Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASLAN004 in Moderate-Severe Atopic Dermatitis
NCT04090229Phase 1Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of eblasakimab in atopic dermatitis (AD) (5 arms), sponsored by ASLAN Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 12 weeks. Started Sep 2019; status: completed.
02
Drugs
eblasakimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04090229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090229.